Coordinated Immunotherapy Regimen for Tumor Eradication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy approaches are often complex, require multiple therapeutic agents, and yield inconsistent results across different cancer types, with existing immune stimulants and checkpoint inhibitors failing to consistently eradicate tumors due to immune evasion mechanisms employed by cancer cells.
Innovation Solution
A coordinated cancer immunotherapy method involving a cancer vaccine regimen combined with concurrent immune stimulation and checkpoint inhibition, with a Th1 bias, using specific cytokines and antibodies like IL-2, IL-12, IL-15, ALT-803, anti-PD1, anti-PD-L1, and anti-CTLA4, to enhance the immune response against tumor-specific antigens and neoepitopes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple therapeutic agents and complex treatment regimens are used to overcome immune evasion mechanisms, then the immune response against tumor antigens is enhanced, but the treatment complexity and duration increase significantly
Solution Approach 1:
The patent combines multiple immunotherapeutic agents (checkpoint inhibitors, immune stimulants, and tumor-specific vaccines) into a coordinated treatment regimen. This merging of therapies addresses multiple immune evasion mechanisms simultaneously, achieving reliable tumor regression while managing complexity through structured scheduling of the combined therapies
2Reliability
If multiple therapeutic agents are administered to address immune evasion, then tumor regression is improved, but the treatment duration and number of administrations increase
Solution Approach 1:
The patent employs a timed treatment sequence where checkpoint inhibition and immune stimulation are administered before vaccine administration. This preliminary action primes the immune system in advance, creating a more responsive state that accelerates the subsequent vaccine-induced immune response, thereby reducing overall treatment duration while maintaining efficacy
3Reliability
If existing immune stimulants and checkpoint inhibitors are used alone, then some immune response is generated, but consistent tumor eradiction is not achieved due to immune suppression in the tumor microenvironment
Solution Approach 1:
The patent creates different local immune environments through sequential therapy: checkpoint inhibitors remove suppression at the system level, immune stimulants create activation at the cellular level, and tumor-specific vaccines generate targeted response at the antigen level. This multi-level approach achieves consistent tumor eradiction across different cancer types by addressing immune suppression at multiple levels simultaneously
Data Source
AI summary
Cancer is treated via a coordinated treatment regimen that use various compounds and compositions that employ a combination vaccination together with immune modulatory treatment and biasing of an immune response towards a Th1 profile.